An international team of researchers led by Professor Morris Brown FRS at Queen Mary University of London found that Baxdrostat, a drug belonging to a new class of aldosterone synthase inhibitors, led to an average fall in blood pressure of 25 mmHg. This is two to three times the reduction typically achieved by a single antihypertensive drug.
This article was originally published on MedicalXpress.com